About this episode
Mesoblast CEO Dr. Silviu Itescu speaks to Lonza about the company’s advanced portfolio of anti-inflammatory allogeneic cellular medicines including remestemcel-L, which is currently being evaluated in a U.S. Phase 3 randomized controlled trial for acute respiratory distress syndrome (ARDS), the principal cause of mortality due to COVID-19 infection.
Get every episode summarized
Each time A view on publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from A view on
Episode 10: A View On Manufacturing Hard-to-manufacture Molecules
A view on
Mar 30, 202614:14failed
Episode 9: A View On Innovating Drug Development and Manufacturing
A view on
Dec 15, 202517:15pending
Episode 8: A View On Process Analytical Technologies
A view on
Nov 11, 202518:32pending
Episode 7: A View On Spray-Drying mRNA-based Therapies
A view on
Jul 28, 202523:23pending